Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 326

1.

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.

McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG.

J Virol. 2011 Jan;85(1):366-77. doi: 10.1128/JVI.01861-10.

2.

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG.

J Virol. 2010 Jan;84(2):1110-23. doi: 10.1128/JVI.01709-09.

3.

Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.

Cullen LM, Blanco JC, Morrison TG.

J Transl Med. 2015 Nov 5;13:350. doi: 10.1186/s12967-015-0705-8.

4.

Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.

Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG.

J Virol. 2014 Sep 1;88(17):10165-76. doi: 10.1128/JVI.01250-14.

5.

Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.

McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG.

J Virol. 2015 Jul;89(13):6835-47. doi: 10.1128/JVI.00384-15.

6.

Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.

Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML.

Antiviral Res. 2014 Nov;111:129-35. doi: 10.1016/j.antiviral.2014.09.005.

7.
8.

Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains.

Schmidt MR, McGinnes LW, Kenward SA, Willems KN, Woodland RT, Morrison TG.

J Virol. 2012 Nov;86(21):11654-62. doi: 10.1128/JVI.01510-12.

9.

Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW.

J Infect Dis. 2011 Oct 1;204(7):987-95. doi: 10.1093/infdis/jir474. Erratum in: J Infect Dis. 2012 Feb;205(3):520.

10.

A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.

Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, Rottier PJ, Haijema BJ, de Haan CA.

PLoS One. 2013 Aug 12;8(8):e71072. doi: 10.1371/journal.pone.0071072.

12.

Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.

Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A.

J Virol. 2014 May;88(9):5100-8. doi: 10.1128/JVI.03194-13. Erratum in: J Virol. 2015 May;89(9):5193.

13.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22.

14.

Assembly and biological and immunological properties of Newcastle disease virus-like particles.

McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, Morrison TG.

J Virol. 2010 May;84(9):4513-23. doi: 10.1128/JVI.01931-09.

15.

Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.

Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H.

Vaccine. 2015 Oct 5;33(41):5406-14. doi: 10.1016/j.vaccine.2015.08.056.

16.

Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Lee JS, Kwon YM, Hwang HS, Lee YN, Ko EJ, Yoo SE, Kim MC, Kim KH, Cho MK, Lee YT, Lee YR, Quan FS, Kang SM.

Vaccine. 2014 Oct 7;32(44):5866-74. doi: 10.1016/j.vaccine.2014.08.045.

17.

Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.

Passmore C, Makidon PE, O'Konek JJ, Zahn JA, Pannu J, Hamouda T, Bitko V, Myc A, Lukacs NW, Fattom A, Baker JR Jr.

Hum Vaccin Immunother. 2014;10(3):615-22.

18.

Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, Cros J, Mertz SE, Jewell NA, Hammond S, Flano E, Durbin RK, García-Sastre A, Durbin JE.

J Virol. 2006 Feb;80(3):1130-9.

19.

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.

Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM.

Vaccine. 2014 Nov 12;32(48):6485-92. doi: 10.1016/j.vaccine.2014.09.030.

20.
Items per page

Supplemental Content

Support Center